UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 6, 2024, the Board of Directors (the “Board”) of ProKidney Corp. (the “Company”) approved, following the recommendation of the Compensation Committee of the Board, the grant of a supplemental equity award (the “Supplemental Equity Award”) to certain employees of the Company, including our Chief Legal Officer, Todd Girolamo, in order to continue to incentivize and retain employees. Each Supplemental Equity Award will be granted on March 1, 2024 (the “Grant Date”) under the Company’s 2022 Incentive Equity Plan. On the Grant Date, Mr. Girolamo will receive a stock option to purchase 234,742 Class A ordinary shares of the Company at an exercise price equal to the fair market value of the Company’s Class A ordinary shares on the Grant Date, which will vest as to 50% of the shares on March 1, 2025, and the remainder in equal monthly installments over the following 12 months.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
PROKIDNEY CORP. |
|
|
|
|
Date: |
February 12, 2024 |
By: |
/s/ Bruce Culleton |
|
|
|
Bruce Culleton |
Document And Entity Information |
Feb. 06, 2024 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Feb. 06, 2024 |
| Entity Registrant Name | PROKIDNEY CORP. |
| Entity Central Index Key | 0001850270 |
| Entity Emerging Growth Company | true |
| Entity File Number | 001-40560 |
| Entity Incorporation, State or Country Code | E9 |
| Entity Tax Identification Number | 98-1586514 |
| Entity Address, Address Line One | 2000 Frontis Plaza Blvd. |
| Entity Address, Address Line Two | Suite 250 |
| Entity Address, City or Town | Winston-Salem |
| Entity Address, State or Province | NC |
| Entity Address, Postal Zip Code | 27103 |
| City Area Code | 336 |
| Local Phone Number | 999-7029 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Entity Ex Transition Period | false |
| Title of 12(b) Security | Class A ordinary shares, $0.0001 par value per share |
| Trading Symbol | PROK |
| Security Exchange Name | NASDAQ |
-8?2
M0$3;8T.P6BP^0"X99K>]9!:G